Lyme vaccine shows strong efficacy in late-stage results but misses primary endpoint
TL;DR
Pfizer and Valneva's Lyme disease vaccine posted 73.2% efficacy starting 28 days after the fourth dose in a late-stage trial, but the study missed its primary endpoint under the worst-case scenario (15.8% efficacy in the initial analysis); a second analysis showed 74.8% efficacy, leading to plans for regulatory submissions, with no Lyme vaccine currently approved.
- Pfizer Lyme vaccine shows more than 70% efficacy but misses key statistical goal NBC News
- Lyme disease vaccine shows 70 percent efficacy, Pfizer says The Washington Post
- Pfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss CNBC
- Pfizer, Valneva Report Strong Efficacy Data From Lyme Vaccine Trial WSJ
- Pfizer and French partner to seek approval for Lyme disease vaccine after late-stage trial MarketWatch
Want the full story? Read the original reporting
Read on NBC News